Michael Horsley, MD
Ophthalmology · Sun City, AZNPI 1871704007
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,720 of the $9,088 with a category attached, or 62.9%. Aerie Pharmaceuticals, Inc. accounts for 71.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $5,959 and has fallen 94.1% since, to $352 in 2025.
Across 148 payments — averaging $61.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Aerie Pharmaceuticals, Inc.$6K
- AbbVie$831
- Alcon$761
- NEW World Medical,inc.$382
- Novartis$141
- Bausch & Lomb, A Division Of Bausch Health US, LLC$137
- plus $361 from 7 others
What the payments were for
- Consulting fees$3003%
- Speaking & faculty fees$5,72063%
- Food & beverage$3,06834%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Aerie Pharmaceuticals, Inc. | 32 | $6,476 |
| AbbVie(2 entities) | 33 | $831 |
| Alcon | 43 | $761 |
| NEW World Medical,inc. | 7 | $382 |
| Novartis | 11 | $141 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $137 |
| Sight Sciences, Inc. | 2 | $130 |
| Amgen(2 entities) | 5 | $99 |
| Shire North American Group Inc | 2 | $38 |
| Kala Pharmaceuticals, Inc. | 2 | $34 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Rayner Intraocular Lenses Limited | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rhopressa$6,060
- Rocklatan$6,060
- Ahmed Glaucoma Valve$300
- Kahook Dual Blade$300
- DURYSTA$122
- OMNI$116
- LUMIGAN$106
How this compares
$9,088 in reported general payments places this provider in the 85th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 152 | $70,486 |
| Prednisolone Acetate | 1,071 | $56,771 |
| RhopressaNetarsudil Mesylate | 59 | $39,083 |
| RocklatanNetarsudil Mesylat/Latanoprost | 61 | $34,415 |
| Alphagan PBrimonidine Tartrate | 33 | $17,886 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 68 | $16,914 |
| RestasisCyclosporine | 13 | $15,198 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $11,727 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 50 | $9,172 |
| Latanoprost | 726 | $7,338 |
| Brinzolamide | 41 | $7,020 |
| Brimonidine Tartrate | 330 | $6,936 |
| Travoprost | 34 | $6,151 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 289 | $4,521 |
| Dorzolamide Hcl | 170 | $3,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan | $831 | $115,297219 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $6,476 | $73,497120 claims |
| AlconSimbrinza | $761 | $16,91468 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Sun City
- Warren HillMesa$1.1M
- Mark BarakatScottsdale$794K
- Anne ZakiSun City West$518K
- Pravin DugelPhoenix$176K
- Derek KunimotoMesa$138K
- Shamil PatelGlendale$116K
- Yuri McKeeMesa$100K
- Nishi ShahPhoenix$92K
- Lisa MihoraPeoria$91K
- George ReissGlendale$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.